Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Moodys
Express Scripts
Medtronic
McKesson
Johnson and Johnson
Dow

Last Updated: October 21, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR IOHEXOL

See Plans and Pricing

« Back to Dashboard

Clinical Trials for Iohexol

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00028626 Portal Vein Embolization in Treating Patients With Liver Metastases From Primary Colorectal Cancer Completed National Cancer Institute (NCI) Phase 2 2001-08-01 RATIONALE: Embolization blocks blood flow to part of an organ and/or tumor. Blocking the portal vein on one side of the liver may cause the opposite side of the liver to increase in size and decrease the risk of liver failure following surgery. PURPOSE: Phase II trial to study the effectiveness of portal vein embolization in treating patients who have liver metastases from primary colorectal cancer.
NCT00028626 Portal Vein Embolization in Treating Patients With Liver Metastases From Primary Colorectal Cancer Completed Memorial Sloan Kettering Cancer Center Phase 2 2001-08-01 RATIONALE: Embolization blocks blood flow to part of an organ and/or tumor. Blocking the portal vein on one side of the liver may cause the opposite side of the liver to increase in size and decrease the risk of liver failure following surgery. PURPOSE: Phase II trial to study the effectiveness of portal vein embolization in treating patients who have liver metastases from primary colorectal cancer.
NCT00157586 Delapril and Manidipine for Nephroprotection in Diabetes (DEMAND) Completed Mario Negri Institute for Pharmacological Research Phase 3 2002-02-01 Diabetes mellitus is one of the most common diseases globally, and is considered epidemic in many developed and newly industrialized nations. Diabetes mellitus represents the single largest cause of end-stage renal disease in the U.S. and Europe. At the same time, the primary cause of early death in diabetic patients are cardiovascular complications. Experimental and clinical studies found that angiotensin converting enzyme inhibitors (ACEi) and calcium channel blockers (CCBs) have a specific renoprotective effect and that this effect can be magnified when the two drugs are used in combination. To formally test this hypothesis we designed the Delapril and Manidipine for Nephroprotection in Diabetes (DEMAND) study, a prospective, randomized, double blind trial aimed to compare the effect of 3 years treatment with the ACEi Delapril (30 mg/day), alone or combined to the CCB Manidipine (10 mg/day), versus conventional (non ACEi, non CCB) therapy on the rate of renal function loss and on the incidence of major cardiovascular events in 342 normo- and micro-albuminuric hypertensive type 2 diabetic patients.
NCT00309283 Somatostatin in Polycystic Kidney: a Long-term Three Year Follow up Study Completed Mario Negri Institute for Pharmacological Research Phase 3 2006-04-01 Autosomal Dominant Polycystic Kidney Disease (ADPKD) is the most common hereditary renal disease, responsible for 8% to 10% of the cases of end stage renal disease (ESRD) in Western countries. At comparable levels of blood pressure control and proteinuria, patients with ADPKD have faster decline in glomerular filtration rate than those with other renal diseases and do not seem to benefit to the same extent of ACE inhibitor therapy. A reasonable explanation for the above findings is that in ADPKD progression is largely dependent on the development and growth of cysts and secondary disruption of normal tissue. Thus, renoprotective interventions in ADPKD - in addition to achieve maximal reduction of arterial blood pressure and proteinuria and to limit the effects of additional potential promoters of disease progression such as dyslipidemia, chronic hyperglycemia or smoking - should also be specifically aimed to correct the dysregulation of epithelial cell growth, secretion, and matrix interactions characteristic of the disease. Evidence that specific receptors for somatostatin are present in the kidney tissue, arises the possibility that somatostatin treatment in patients with ADPKD might inhibit fluid formation and eventually induce the shrinking of renal cysts.To evaluate the tolerability and the safety of long-acting somatostatin in ADPKD patients, a prospective cross-over controlled study has been recently performed. This pilot study demonstrated the safety of six month treatment of long-acting somatostatin in patients with ADPKD. Moreover, the percent increase of total kidney volume was significantly lower in patients on somatostatin than in placebo. Overall, these findings provide the basis for designing a long-term study in ADPKD patients aimed to document the efficacy of the somatostatin treatment in preventing further increase or even reducing the total kidney volume and the renal volume taken up by small cysts, eventually halting kidney disease progression.
NCT00478556 Omnipaque Versus Gastroview as Oral Contrast for Abdominal and Pelvic CT Completed GE Healthcare Phase 4 2007-08-01 Patients who are scheduled by their health care provider for routine computed tomography (CT) scan will be asked to participate in this study. The primary purpose is to determine if there is a difference in patient preference for Omnipaque versus Gastroview as oral contrast for abdominal pelvic CT. A secondary objective is to evaluate if there is significant difference in bowel opacification for the two agents.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Iohexol

Condition Name

Condition Name for Iohexol
Intervention Trials
Acute Kidney Injury 4
Healthy 4
HIV 2
Renal Insufficiency 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Iohexol
Intervention Trials
Kidney Diseases 7
Acute Kidney Injury 5
Renal Insufficiency 5
Diabetes Mellitus, Type 2 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Iohexol

Trials by Country

Trials by Country for Iohexol
Location Trials
United States 33
France 7
Italy 5
Canada 5
Korea, Republic of 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Iohexol
Location Trials
California 6
Georgia 2
New York 2
Florida 2
Washington 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Iohexol

Clinical Trial Phase

Clinical Trial Phase for Iohexol
Clinical Trial Phase Trials
Phase 4 12
Phase 3 8
Phase 2/Phase 3 1
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Iohexol
Clinical Trial Phase Trials
Completed 22
Not yet recruiting 10
Recruiting 7
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Iohexol

Sponsor Name

Sponsor Name for Iohexol
Sponsor Trials
GE Healthcare 3
Mario Negri Institute for Pharmacological Research 3
MediBeacon 3
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Iohexol
Sponsor Trials
Other 48
Industry 25
NIH 5
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Dow
AstraZeneca
Baxter
Express Scripts
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.